Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498574 | 0.93 | TDP1 (0.34) | TP53LMNAPOLBMAPTTDP1 | |
| SCHEMBL23499013 | 0.92 | KDM4E (0.36) | TP53LMNAPOLBTDP1HTT | |
| SCHEMBL23498583 | 0.79 | CA12 (0.40) | LMNAMAPTTDP1ALDH1A1CYP3A4 | |
| SCHEMBL18040419 | 0.76 | KEAP1 (0.44) | POLBMAPTKEAP1NFE2L2NOTUM | |
| SCHEMBL5553127 | 0.75 | TP53 (0.39) | TP53LMNAPOLBMAPTNOTUM | |
| SCHEMBL23498584 | 0.73 | KMT2A (0.41) | LMNAPOLBMAPTTDP1ALDH1A1 | |
| SCHEMBL9959156 | 0.72 | TP53 (0.40) | TP53LMNAPOLBMAPTNOTUM | |
| SCHEMBL23498571 | 0.72 | KMT2A (0.43) | LMNATDP1ALDH1A1RECQLCYP3A4 | |
| SCHEMBL23498965 | 0.71 | TP53 (0.44) | TP53LMNAPOLBNOTUM | |
| SCHEMBL23499048 | 0.70 | DRD4 (0.42) | LMNAPOLBMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-06 | — | — | US | disclosed |
| WO-2021119081-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021119081-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | TP53 385/4885LMNA 2483/4885POLB 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.